CC BY-NC-ND 4.0 · Asian J Neurosurg 2017; 12(04): 727-730
DOI: 10.4103/ajns.AJNS_39_15
Case Report

Tumor recurrence in a glioblastoma patient after discontinuation of prolonged temozolomide treatment

Wei-Lung Tseng
Department of Surgery, National Taiwan University Hospital, Yun-Lin Branch, Douliu, Yunlin
,
Hsu-Hsien Hsu
Department of Surgery, National Taiwan University Hospital, Yun-Lin Branch, Douliu, Yunlin
,
Yun Chen
1   Department of Surgery, Far Eastern Memorial Hospital, Pan-Chiao, New Taipei
2   Department of Chemical Engineering and Materials Science, Yuan Ze University, Chung-Li, Taoyuan, Taiwan
,
Sheng-Hong Tseng
Department of Surgery, National Taiwan University Hospital, Yun-Lin Branch, Douliu, Yunlin
› Author Affiliations

There is no consensus regarding the duration of temozolomide (TMZ) treatment for glioblastoma multiforme (GBM). We report a 53-year-old woman who had a left frontal GBM. The tumor showed good response to TMZ treatment, which was discontinued after 5.5 years with recurrence of tumor at the posterior fossa 6 months later, although there was no definite tumor recurrence in the left frontal region. The tumor failed to respond to the reinstitution of TMZ therapy. Continuous TMZ treatment may be necessary in GBM patients on prolonged TMZ treatment despite improved neurological condition and imaging studies revealing marked tumor regression.



Publication History

Article published online:
20 September 2022

© 2017. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India